Financial News · Live Terminal

Page 140 of 171

Research Alert: CFRA Maintains Buy Opinion On Shares Of Autoliv Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain a 12-month price target of $145, based on a 2027 P/E of 11.3x, a justified discount to ALV's five-year forward P/E of 14.0x. Following a much stronger-than-expected Q1, we reiterate our Buy opinion and $145 price target on ALV. We lower our 2026 adjusted EPS estimate by $0.20 to $11.00 but keep 2027's unchanged at $12.80. In our view, the release went a long way toward easing demand-related concerns, both for the company and broader auto supplier industry. ALV remains one of our top picks in the auto supplier space, as justified by its strong track record of execution (this was its sixth consecutive earnings beat), organic net sales growth that continues to exceed global light vehicle growth by a wide margin thanks to its exposure to higher-growth manufacturers and countries (i.e., India), and generous cash returns to shareholders. While we have concerns regarding ALV's ability to hit full-year operating margin guidance, its organic net sales growth is running ahead of expectations.

$ALV

Research22d ago

Research Alert: CFRA Keeps Hold Opinion On Shares Of Ally Financial Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After digesting Q1 earnings and accounting for the recently-improved geopolitical environment, we increase our 12-month target price by $11 to $51, 7.8x our 2027 EPS estimate, a discount to the peer average of 10.1x given ALLY's more volatile earnings. We increase our 2026 EPS by $0.24 to $5.46 and raise 2027's by $0.36 to $6.55. Our revenue projections are $9.0 billion in 2026 and $9.6 billion in 2027. ALLY delivered encouraging Q1 results, with continued improvement in credit quality. After several years of weakness, loan growth has now accelerated for three consecutive quarters, a positive development we have been watching closely. Q1 was particularly strong, with consumer applications reaching an all-time high of 4.4 million. That said, the interest rate environment remains a headwind, as rate cuts are unlikely to materialize until late 2026 or 2027. On the positive side, ALLY and its banking peers stand to benefit from the newly-proposed Basel III capital rules. Shares yield 2.7%.

$ALLY

Research22d ago

Research Alert: CFRA Maintains Buy Opinion On Shares Of Corning Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target by $67 to $190, 60.7x our 2026 EPS estimate, a notable premium to its three-year historical average P/E at 22.5x (corrected from 65.7x previously). We see this premium as warranted, similar to competitor LITE, given the potential growth AI demand could generate. We increase our 2026 EPS estimate by $0.02 to $3.13 and raise 2027's by $0.06 to $3.91. Corning has experienced substantial growth since the roll-out of its Springboard plan, including sales growth of about 40% and earnings growth of almost 90%, as well as improvements in operating margin and return on invested capital (ROIC) into the mid-teens. There is strong demand in the optical communications space, especially related to AI-driven data center expansion, with Corning's new fiber products proving successful and surpassing market expectations. Corning sees a large opportunity in the conversion of copper to optics in data centers, which is happening faster than initially anticipated, driving further growth potential.

$GLW

Research22d ago

Research Alert: CFRA Keeps Hold Recommendation On Shares Of Truist Financial Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target price at $56, based on 10.8x our 2027 EPS estimate, a premium to TFC's five-year forward P/E average of 10.5x given an improving regulatory environment, an uptick in capital return, and improving efficiency. We raise our 2026 EPS view by $0.02 to $4.59 and keep 2027's at $5.18. We maintain a Hold rating on the stock, as the bank tends to take three steps forward then two steps back. This quarter, we were encouraged by strong fee income performance, with Investment Banking and Trading delivering their highest quarterly revenue since 2021. This is a trend we expect to continue as geopolitical conflicts appear to be subsiding. However, net interest income disappointed in Q1 and balance sheet growth remains inconsistent. On a positive note, TFC has become more optimistic and established a new long-term return on tangible common equity (ROTCE) target of 16%-18%. While this is encouraging, TFC has considerable work ahead as its ROTCE has not exceeded 14% for eight consecutive quarters.

$TFC

Research22d ago

Research Alert: CFRA Keeps Hold Recommendation On Shares Of Fifth Third Bancorp

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After reviewing Q1 earnings, we reduce our 12-month target price by $1 to $56, 11.2x our 2027 EPS estimate, a wider risk premium than FITB's five-year forward P/E average of 10.3x given healthy fee income expectations and an improving regulatory environment. We lower our 2026 EPS estimate by $0.07 to $4.09 but increase 2027's by $0.10 to $5.02. This was a transformative quarter for FITB, which completed its largest acquisition in history, vaulting from the 19th to the 13th largest U.S. bank by assets. While we continue to believe the acquisition will create headwinds to organic growth, it delivered immediate benefits: credit quality improved markedly, and net interest margin expanded to 3.30%, the highest level since 2022. The trade-off came in capital, with the CET1 ratio declining 80 bps Q/Q to 10.0%, among the lowest in the peer group. However, given the likely relief from newly-proposed Basel III capital rules, we view this more modest capital position as acceptable.

$FITB

Research22d ago

Research Alert: CFRA Lowers Rating On Polestar Automotive Holding To Strong Sell From Sell

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target to $5 from $8, based on our DCF analysis and implying a premium to tangible book value. Our adjusted EBITDA estimates decline modestly on lower volume and higher cost assumptions, as we now assume PSNY's sales volume increases only 3% in 2026. PSNY's Q4 net loss of -$799M was well short of the -$452M consensus, but up from -$1,183M in Q4 2024. More importantly, looking ahead, management's guidance was cautious, although it still expects its global retail sales volumes to increase by low double digits over 2025 sales of 60,119 vehicles. We think this guidance is likely to prove aggressive considering slowing global EV sales growth. Regardless, shares have outperformed recently despite a December 1-for-30 reverse stock split, and we expect cash burn to remain high, raising the risk of a restructuring absent additional lifelines from Volvo/Geely Automobile Holdings Ltd. (175 HK 25 ****) or others. We forecast free cash flow of -$1.2B in 2026 after posting -$1.37B in 2025.

$PSNY

Research22d ago

Research Alert: CFRA Maintains Buy Rating On Shares Of State Street Corp.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our target by $19 to $164, using a forward P/E of 13.3x our 2026 earnings estimate, compared to the three- and five-year historical averages of 13.5x and 13.0x, respectively. We think strong execution and low-teen Y/Y earnings growth are key drivers. We lift our 2026 EPS view by $0.65 to $12.35 and 2027's by $1.00 to $13.50 on projected revenue of $15.4B in 2026 and $15.7B in 2027. STT reported exceptional Q1 2026 results, demonstrating the strength of its diversified fee-based business model and disciplined execution. It realized return on equity of 11.6% and return on tangible common equity of 17.6%, vs 10.6% and 16.4% a year ago due to some one-time items. With book value at $87.33 and net tangible book value at $56.59, the current price multiples to these metrics are 1.7x and 2.6x, which we view as reasonable, provided we see earnings growth. STT shares currently trade at a 510-bp discount to the S&P 500, and capital returns were $400M in share buybacks and $233M in dividends in Q1 2026.

$STT

Research22d ago

Research Alert: CFRA Maintains Hold Opinion On Shares Of The Travelers Companies, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain our 12-month target price of $315, valuing TRV shares at 11.4x our 2026 operating EPS estimate of $27.74 (raised by $2.09 on April 17) and at 11.2x our 2027 EPS estimate of $28.05 (raised by $0.40). Our target multiples assume TRV shares trade in line with the three-year average forward multiple of 11x and compare to the peer average of 12x. At current levels, we view the shares as fairly valued, versus peer and historical averages. We applaud TRV's risk management skills, and note the turnaround in Q1 underwriting profitability (a $1.17B profits versus a $305M year-ago loss) amid a 66% drop in catastrophes and improved favorable prior-year loss development trends. However, TRV's top-line growth has stalled amid a more competitive pricing environment, and Q1 operating revenues were flat, Y/Y, and net written premiums fell by 2%, Y/Y. We think the top-line erosion removes a catalyst from the shares.

$TRV

Research23d ago

Research Alert: CFRA Initiates Coverage On Shares Of Medline Inc. With A Hold Rating

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month price target of $52 is 31.5x our 2027 EPS estimate (starts at $1.65; 2026 EPS estimate is $1.47), a premium to MDLN's 28.6x forward average since IPO in December 2025. Though MDLN generates significantly lower revenue than large pharma distributors such Cardinal Health (CAH 212 ****), MDLN's vertically integrated model and vast product portfolio supports much stronger operating margins than peers, in our view. We anticipate 8.5%-9.0% sales growth in 2026, toward the high end of MDLN's organic growth guidance, supported by new customer signings, though offset somewhat by potential headwinds for health care utilization levels due to coverage losses from the OBBBA legislation and the recent expiration of the ACA enhanced premium tax credits, which may pose a drag on medical-surgical product sales. Positively, we see strong sales visibility with $2.4B of new customer signings during 2025, including a long-term partnership with the U.S. Department of Veterans Affairs (VA).

$MDLN

Research23d ago

Lassonde Industries Maintained at Buy at Stifel Canada; Price Target Kept at C$280.00

Stifel Canada on Friday reiterated its buy rating on the shares of Lassonde Industries (LAS-A.TO) and its C$280.00 price target as it hosted investor meetings with fruit juice and snacks company."We recently hosted investor meetings with Lassonde. Most of the discussions focused on growth plans and investments. We believe Lassonde is under-appreciated given its depressed valuation. The company has (1) organic revenue growth opportunities from recently introduced formats and further penetration in various distribution channels, (2) cost savings opportunities with the New Jersey plant, and (3) M&A opportunities. Lassonde's recent acquisition, Summer Garden, has been a success with a smooth integration and healthy synergy realization. This provides the company with credibility to make further acquisitions. It is not clear how long valuation will remain depressed, below 10x forward earnings, and what catalyst could help valuation re-rate closer to its historical level of 13x. A potential return to historical valuation would represent a stock price of $360, up more an upside of more than 50% from current levels. We believe the current share price provides investors with an appealing entry point," analyst Martin Landry wrote.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $230.00, Change: $-0.21, Percent Change: -0.09%

$LAS-A.TO

Research23d ago

Research Alert: CFRA Keeps Hold Opinion On Adss Of Ericsson

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our Hold rating and raise our 12-month target to USD13 from USD11, based on an EV/EBITDA multiple of 6.9x (7.0x), in line with its five-year average, applied to our 2027 EBITDA estimate of SEK47.9B. The multiple reflects a cautious stance on margin expansion given input cost pressures and a still-flat Radio Access Network (RAN) market. As Q1 2026 results were seasonally in line with expectations, we maintain our 2026 revenue estimate at SEK243B and 2027 at SEK249B, supported by stable demand from 5G deployments and improving contribution from Cloud Software and Services, partly offset by weaker North America trends. Hence, we also maintain our 2026 EPADS at SEK8.99 and 2027 at SEK9.23, reflecting cost discipline and improving mix, partly offset by ongoing input cost pressures. Earnings growth remains gradual, with near-term performance influenced by deal timing and cost headwinds, while margin improvement is expected to be supported by efficiency measures and improving business mix over time.

$ERIC

Research23d ago

Research Alert: CFRA Maintains Buy Opinion On Shares Of Netflix, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our $115 target price based on a forward TEV/EBITDA of 28.5x compared to the three-year historical average at 32.5x and the five-year at 32.1x. Taking into account the strong Q1 2026 earnings beat and the seasonally weaker Q2 2026, we are raising our 2026 EPS estimate by $0.60 to $3.75 and increasing 2027's by $0.20 to $4.00 on projected revenue of $51.2B (no change from prior) and 2027 at $56.2B (prior $57.0B). Share price is anticipated to trade lower with weaker guidance for the seasonally low Q2 2026 results guiding $12.2B in revenue and narrower gross margins, a low for the year. NFLX share price movement comes after a parabolic upward move in the stock in the past weeks. First, the announcement that it was walking away from the WBD takeover battle, and second, an overall equity market rise that favors growth stocks like NFLX, in our opinion. Whether NFLX is a growth stock is the key debate, with organic top line growth in the mid-teens and wider margins driving higher profitability.

$NFLX

Research23d ago

Research Alert: CFRA Reiterates Strong Buy Opinion On Shares Of Ati Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We increase our 12-month target price to $179 from $154, on an EV/EBITDA of 19.0x our 2027 EBITDA estimate, a premium to ATI's trailing-12-month average forward EV/EBITDA of 16.9x but a discount to peers' average forward EV/EBITDA of 26.8x. We raise our 2026 EPS estimate by $0.08 to $4.43 and our 2027 EPS forecast by $0.28 to $5.40. We see ATI continuing to benefit from robust aerospace & defense demand, which represented 68% of Q4 2025 sales, supported by Boeing and Airbus backlogs and long-term supply agreements. Management's 2026 adjusted EBITDA guidance midpoint of $1.0B implies 16% Y/Y growth, with improving profitability expected in 2H 2026 as maintenance normalizes and aerospace mix strengthens toward 20%+ margins. We believe ATI's expanded titanium capacity, operating leverage, and customer-funded investments in proprietary nickel alloys position it well to capture aerospace industry growth through 2027. We maintain our Strong Buy recommendation.

$ATI

Research23d ago

Research Alert: State Street Corp. Delivers Earnings And Revenue Beat

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:STT delivered strong Q1 2026 results with adjusted EPS of $2.84, beating consensus of $2.64, and total revenue of $3.80B (+16% Y/Y) driven by broad-based fee growth. The company achieved ROE of 11.6% and ROTCE of 17.6%, with record AUC/A of $54.5T (+17%) and AUM of $5.6T (+20%), while maintaining cost discipline with 86 basis points of operating leverage. We view STT's improved cost controls and strategic partnerships positively as key growth drivers supporting the investment thesis. Management maintained 2026 guidance for fee revenue growth of 4%-6%, single-digit NII growth, and expense increases of only 3%-4%, targeting 100 basis points of operating leverage. We believe STT is well positioned with its strong market position in asset servicing and management, and ability to manage costs amid moderating NII growth ahead. The company returned $633M to shareholders through $400M repurchases and $233M dividends, with a CET1 ratio of 10.6% providing adequate capital flexibility for continued growth.

$STT

Research23d ago

BNP Paribas Downgrades QUALCOMM to Neutral From Outperform, Cuts Price Target to $120 From $180

QUALCOMM (QCOM) has an average rating of Hold and mean price target of $148.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$QCOM

Research23d ago

BNP Paribas Upgrades Apple to Outperform From Neutral, Raise Price Target to $300 From $260

Apple (AAPL) has an average rating of overweight and mean price target of $301.37, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$AAPL

Research23d ago

Wells Fargo Downgrades Soleno Therapeutics to Equal Weight From Overweight, Adjusts PT to $53 From $110

Soleno Therapeutics Inc (SLNO) has an average rating of Hold and mean price target of $59.33, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$SLNO

Research23d ago

Research Alert: Ally: Q1 Earnings Beat As Credit Quality Improves

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ALLY posted solid Q1 results, with operating EPS of $1.11 vs. $0.58 in the prior year, beating consensus by $0.17, while revenue of $2.10B missed consensus by 2%. Net interest margin expanded 17 bps Q/Q to 3.48%, outperforming many peer banks that saw contraction, reflecting structural benefits from balance sheet optimization and disciplined deposit pricing strategy. Credit quality continued to improve, with net charge-offs falling 29 bps to 1.21% and retail auto delinquencies declining 17 bps to 4.60%, demonstrating disciplined underwriting benefits. The $467M provision for credit losses was primarily due to reserve builds from asset growth rather than credit deterioration. Its strong capital position, with a CET1 ratio of 10.1% (up 60 bps) and liquidity of $65.8B, provided strategic flexibility for the $147M in share repurchases executed. The digital banking platform maintained strong momentum with 68 consecutive quarters of customer additions, reaching 3.5M retail deposit customers and $146B in balances.

$ALLY

Research23d ago

Research Alert: Psny: Q4 2025 Short Of Expectations; Cash Flow Remains Problematic

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Polestar Automotive (PSNY) posted Q4 net loss of -$799M, well short of the -$452M consensus but up from -$1,183M in Q4 2024. Revenue rose 54% Y/Y to $887M ($77M ahead of consensus), reflecting a 27% increase in total vehicle sales to 15,608 units. PSNY's gross margin came in at -38%, an improvement from -147% in the year-ago quarter. PSNY's liquidity position improved substantially with year-end cash of $1.16B, up from $739M a year earlier, boosted by $1.2B in equity raises since June 2025 and $639M in debt-to-equity conversions. PSNY's 2025 free cash flow of -$1.37B worsened from -$1.35B in 2024. The company said it continues to expect its global retail sales volumes to increase by a low double-digit rate versus 2025 sales of 60,119 vehicles (+34% Y/Y), saying the global environment is expected to remain highly uncertain in 2026. In our view, risks surrounding PSNY remain very high, and its guidance doesn't inspire confidence that its free cash flow is going to improve materially in 2026.

$PSNY

Research23d ago

Stifel Nicolaus Upgrades Onto Innovation to Buy From Hold, Adjusts Price Target to $350 From $220

Onto Innovation (ONTO) has an average rating of Buy and mean price target of $312.14, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$ONTO

Showing 2781-2800 of 3405